Analysts Set Guardant Health, Inc. (NASDAQ:GH) PT at $42.63

Guardant Health, Inc. (NASDAQ:GH) has received an average rating of “Buy” from the sixteen brokerages that are covering the firm, Marketbeat.com reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $42.63.

Several equities research analysts have commented on the company. Sanford C. Bernstein cut their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Leerink Partners reduced their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group boosted their price target on shares of Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Finally, Barclays assumed coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now directly owns 7,648 shares in the company, valued at $228,675.20. This trade represents a 27.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,548 shares of company stock valued at $179,782 over the last ninety days. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Lord Abbett & CO. LLC purchased a new position in shares of Guardant Health in the third quarter worth about $15,624,000. Cerity Partners LLC grew its position in Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after acquiring an additional 68,883 shares during the last quarter. Geode Capital Management LLC increased its stake in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after purchasing an additional 29,686 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Guardant Health by 1,282.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock valued at $28,128,000 after purchasing an additional 1,137,482 shares during the last quarter. Finally, Pier Capital LLC boosted its stake in shares of Guardant Health by 36.7% during the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after purchasing an additional 42,575 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Stock Down 3.2 %

Shares of NASDAQ GH opened at $46.09 on Tuesday. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89. The stock has a market cap of $5.69 billion, a price-to-earnings ratio of -10.87 and a beta of 1.32. The company’s fifty day moving average is $37.94 and its 200-day moving average is $30.59.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The business had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. On average, research analysts anticipate that Guardant Health will post -3.43 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.